A Prospective, Multicenter Study Investigating the Effectiveness of an Oscillating Positive Expiratory Pressure (OPEP) Device in COPD Patients in Québec, Canada

RATIONALE: Clinical benefits of oscillating positive expiratory pressure (OPEP) devices have been previously demonstrated in many respiratory diseases, including chronic obstructive pulmonary disease (COPD). This study aimed to provide patient-reported outcomes of OPEP treatment in COPD patients in Québec, Canada. METHOD: OPEP (TMI) devices were provided, with instructions on usage and technique. CAT assessments were collected at baseline and 6 and 12 weeks. At the final visit, patients were asked whether they would continue to use the device and provided ratings on usability and satisfaction. RESULT: Data were analyzed from 46 patients. The average CAT score at 6 weeks was significantly lower than baseline (19.02 ± 6.59 vs. 23.65 ± 6.44, p < 0.00001), with 31/44 patients (70.5%) reaching the minimum clinically important difference (MCID). Scores decreased further at 12 weeks (16.15 ± 6.06), a significant improvement from 6 weeks (p = 0.0052). MCID was reached by 39/44 patients (84.8%) after 12 weeks of treatment. Average 6 and 12 week mucus scores (2.59 ± 1.02 and 2.28 ± 1.13, respectively) were both significantly lower than baseline (3.63 ± 0.97; p < 0.00001 at 6 and 12 weeks). Regarding device feedback, 43/44 patients (97.7%) would continue using the device. The proportion of patients that provided 4/5 or 5/5 satisfaction ratings was 40/45 (88.9%), 43/45 (95.6%), and 40/45 (88.9%) for ease of use, quality, and overall satisfaction, respectively. No device-related adverse events were reported. CONCLUSION: OPEP in conjunction with standard of care in COPD patients to manage symptoms and enhance quality of life. Patient feedback shows high levels of acceptance and perceived value of the device.